127 related articles for article (PubMed ID: 28428239)
1. MDS with isolated del(5q) and internuclear bridging.
Xu Z; McGowan-Jordan J
Blood; 2017 Apr; 129(16):2333. PubMed ID: 28428239
[No Abstract] [Full Text] [Related]
2. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
Jaju RJ; Jones M; Boultwood J; Kelly S; Mason DY; Wainscoat JS; Kearney L
Genes Chromosomes Cancer; 2000 Nov; 29(3):276-80. PubMed ID: 10992302
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndrome associated with isolated del (5q) chromosome abnormality ("5q- syndrome").
Maslak P
Blood; 2007 Dec; 110(12):3825. PubMed ID: 18062093
[No Abstract] [Full Text] [Related]
4. Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.
Godon C; Talmant P; Garand R; Accart F; Bataille R; Avet-Loiseau H
Genes Chromosomes Cancer; 2000 Dec; 29(4):350-2. PubMed ID: 11066080
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow morphology in myelodysplastic syndrome associated with isolated del(5q).
Naresh KN; Reid A
Am J Hematol; 2010 Aug; 85(8):609-10. PubMed ID: 20658591
[No Abstract] [Full Text] [Related]
6. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.
Talati C; Sallman D; List AF
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):629-635. PubMed ID: 30097406
[TBL] [Abstract][Full Text] [Related]
7. Blood consult: treating del(5q) myelodysplastic syndromes.
Mukherjee S; Tiu RV; Sekeres MA
Blood; 2012 Jan; 119(2):342-4. PubMed ID: 22039258
[No Abstract] [Full Text] [Related]
8. Concurrent
Tremblay-LeMay R; Chang H
Blood; 2018 Jul; 132(1):112. PubMed ID: 29976782
[No Abstract] [Full Text] [Related]
9. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.
Keerthivasan G; Mei Y; Zhao B; Zhang L; Harris CE; Gao J; Basiorka AA; Schipma MJ; McElherne J; Yang J; Verma AK; Pellagatti A; Boultwood J; List AF; Williams DA; Ji P
Blood; 2014 Jul; 124(5):780-90. PubMed ID: 24891322
[TBL] [Abstract][Full Text] [Related]
10. Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases.
Himmelmann A; Tchinda J
Leuk Res; 2012 May; 36(5):656-7. PubMed ID: 22177945
[No Abstract] [Full Text] [Related]
11. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
12. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
13. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.
Giagounidis AA; Germing U; Haase S; Hildebrandt B; Schlegelberger B; Schoch C; Wilkens L; Heinsch M; Willems H; Aivado M; Aul C
Leukemia; 2004 Jan; 18(1):113-9. PubMed ID: 14586479
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
15. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
[TBL] [Abstract][Full Text] [Related]
16. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
17. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
[TBL] [Abstract][Full Text] [Related]
18. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
20. A paediatric myelodysplastic syndrome with 5q deletion associated with Fanconi anaemia.
Kornreich L; Soulier J; Grange B; Girard S; Ouchée-Chardin M; Ceraulo A
Pediatr Blood Cancer; 2020 Jul; 67(7):e28369. PubMed ID: 32379395
[No Abstract] [Full Text] [Related]
[Next] [New Search]
